Table 3. Summary of the crude event rates for stroke in the main analysis and the two sensitivity analyses.
| Main analysis | Sensitivity analysis 11) | Sensitivity analysis 22) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apixaban (n = 10,548) | Dabigatran (n = 11,414) | Rivaroxaban (n = 17,779) | Warfarin (n = 8,648) | Apixaban (n = 10,548) | Dabigatran (n = 11,414) | Rivaroxaban (n = 17,779) | Warfarin (n = 8,648) | Apixaban (n = 10,548) | Dabigatran (n = 11,414) | Rivaroxaban (n = 17,779) | Warfarin (n = 8,648) | |
| Crude incidence rates | Crude incidence rates | Crude incidence rates | ||||||||||
| IS | 7.25 | 6.54 | 6.20 | 10.33 | 2.91 | 3.02 | 3.11 | 5.58 | 2.89 | 3.02 | 3.09 | 5.52 |
| HS | 1.13 | 0.69 | 1.12 | 1.52 | NA | NA | NA | NA | 0.41 | 0.09 | 0.56 | 0.65 |
HS, haemorrhagic stroke; ICD-10, International Classification of Diseases 10th Revision; IS, ischemic stroke; NA, not assessed.
Incidence rates were calculated as the number of patients with the event divided by 100 person-years.
1) In sensitivity analysis 1, ischemic stroke events were restricted to those meeting all of the following criteria: an inpatient claim for ischemic stroke (ICD-10 code I63, I693 or G459) as the primary diagnosis, a claim at the Department of Neurology and Neurosurgery and brain CT/MRI records.
2) In sensitivity analysis 2, the ischemic stroke and haemorrhagic stroke events were restricted to those meeting all of the following criteria: an inpatient claim for ischemic stroke (ICD-10 code I63 or G459) or haemorrhagic stroke (ICD-10 code I61 or I62) as the primary diagnosis, a claim at the Department of Neurology and Neurosurgery and brain CT/MRI records.